Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience

M. Akif Yesilipek, Vedat Uygun, Alphan Kupesiz, Gulsun Karasu, Gulyuz Ozturk, Mehmet Ertem, İlgen Şaşmaz, Hayriye Daloğlu, Elif Güler, Volkan Hazar, Tunç Fisgin, Gülay Sezgin, Savaş Kansoy, Barış Kuşkonmaz, Burcu Akıncı, Namık Özbek, Elif Ünal İnce, Seda Öztürkmen, Funda Tayfun Küpesiz, Koray YalçınSema Anak, Ceyhun Bozkurt, Musa Karakükçü, Serhan Küpeli, Davut Albayrak, Haldun Öniz, Serap Aksoylar, Fatma Visal Okur, Canan Albayrak, Fatma Demir Yenigürbüz, İkbal Ok Bozkaya, Talia İleri, Orhan Gürsel, Barbaros Şahin Karagün, Gülen Tüysüz Kintrup, Suna Çelen, Murat Elli, Basak Adaklı Aksoy, Ebru Yılmaz, Atila Tanyeli, Şule Turan Akyol, Zuhal Önder Siviş, Gülcihan Özek, Duygu Uçkan, İbrahim Kartal, Didem Atay, Arzu Akyay, Özlem Arman Bilir, Hasan Fatih Çakmaklı, Emin Kürekçi, Barış Malbora, Sinan Akbayram, Hacı Ahmet Demir, Suar Çakı Kılıç, Adalet Meral Güneş, Emine Zengin, Salih Özmen, Ali Bülent Antmen

Araştırma sonucu: Dergi katkısıMakalebilirkişi

13 Alıntılar (Scopus)

Özet

We report the national data on the outcomes of hematopoietic stem cell transplantation (HSCT) for thalassemia major (TM) patients in Turkey on behalf of the Turkish Pediatric Stem Cell Transplantation Group. We retrospectively enrolled 1469 patients with TM who underwent their first HSCT between 1988 and 2020 in 25 pediatric centers in Turkey. The median follow-up duration and transplant ages were 62 months and 7 years, respectively; 113 patients had chronic graft versus host disease (cGVHD) and the cGVHD rate was 8.3% in surviving patients. Upon the last visit, 30 patients still had cGvHD (2.2%). The 5-year overall survival (OS), thalassemia-free survival (TFS) and thalassemia-GVHD-free survival (TGFS) rates were 92.3%, 82.1%, and 80.8%, respectively. cGVHD incidence was significantly lower in the mixed chimerism (MC) group compared to the complete chimerism (CC) group (p < 0.001). In survival analysis, OS, TFS, and TGFS rates were significantly higher for transplants after 2010. TFS and TGFS rates were better for patients under 7 years and at centers that had performed over 100 thalassemia transplants. Transplants from matched unrelated donors had significantly higher TFS rates. We recommend HSCT before 7 years old in thalassemia patients who have a matched donor for improved outcomes.

Orijinal dilİngilizce
Sayfa (başlangıç-bitiş)760-767
Sayfa sayısı8
DergiBone Marrow Transplantation
Hacim57
Basın numarası5
DOI'lar
Yayın durumuYayınlanan - May 2022
Harici olarak yayınlandıEvet

Parmak izi

Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience' araştırma başlıklarına git. Birlikte benzersiz bir parmak izi oluştururlar.

Bundan alıntı yap